» Articles » PMID: 32367630

LINC00641 Hinders the Progression of Cervical Cancer by Targeting MiR-378a-3p/CPEB3

Overview
Journal J Gene Med
Date 2020 May 6
PMID 32367630
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: LINC00641 was found to act in anti-tumor manner in several types of cancers. Nonetheless, the detailed functions of LINC00641 have not been determined in cervical cancer (CC).

Methods: The expression of LINC00641, miR-378a-3p and CPEB3 was examined using a quantitative reverse transcriptase-polymerase chain reaction. The relationships between LINC00641 and its downstream mechanism were illustrated by RNA pull-down and luciferase reporter experiments.

Results: LINC00641 was found to be under-expressed in CC cell lines. By overexpressing LINC00641, cell proliferative, migratory and invasive abilities, as well as epithelial mesenchymal transition (EMT) characteristics, were inhibited, whereas the rate of apoptosis was increased. Next, a starBase search (http://starbase.sysu.edu.cn) was applied to select microRNAs that had binding sequences with LINC00641. By up-regulating LINC00641 expression, miR-378a-3p expression displayed the strongest decline. Moreover, miR-378a-3p was found to be up-regulated in CC cell lines. In addition, LINC00641 hindered the progression of CC by decreasing miR-378a-3p expression. CPEB3 was discovered as a downstream target of miR-378a-3p and was under-expressed in CC cells. Furthermore, knockdown of CPEB3 could counter the influence of an overexpression of LINC00641 with respect to CC progression.

Conclusions: LINC00641 suppressed the progression of CC by targeting miR-378a-3p/CPEB3, suggesting that LINC00641 may have positive therapeutic impact for treatment for CC.

Citing Articles

Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.

Hashemi M, Khosroshahi E, Asadi S, Tanha M, Ghatei Mohseni F, Abdolmohammad Sagha R Noncoding RNA Res. 2024; 10:1-15.

PMID: 39296640 PMC: 11406677. DOI: 10.1016/j.ncrna.2024.08.002.


Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma.

Chen D, Li Q, Xu Y, Wei Y, Li J, Zhu X Cancer Cell Int. 2023; 23(1):316.

PMID: 38066643 PMC: 10709922. DOI: 10.1186/s12935-023-03147-7.


Downregulation of N6-methyladenosine-modified LINC00641 promotes EMT, but provides a ferroptotic vulnerability in lung cancer.

Xi S, Ming D, Zhang J, Guo M, Wang S, Cai Y Cell Death Dis. 2023; 14(6):359.

PMID: 37311754 PMC: 10264399. DOI: 10.1038/s41419-023-05880-3.


Depicting the Implication of miR-378a in Cancers.

Qin Y, Liang R, Lu P, Lai L, Zhu X Technol Cancer Res Treat. 2022; 21:15330338221134385.

PMID: 36285472 PMC: 9608056. DOI: 10.1177/15330338221134385.


LincRNAs and snoRNAs in Breast Cancer Cell Metastasis: The Unknown Players.

Louca M, Gkretsi V Cancers (Basel). 2022; 14(18).

PMID: 36139687 PMC: 9496948. DOI: 10.3390/cancers14184528.